Loading...

뉴스 목록

New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

2020-06-16


New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new drug for insomnia, in the US market for the treatment of adult insomnia. It is estimated that about 30% of adults worldwide have symptoms of insomnia, many of which last for months to years.
Dayvigo's active pharmaceutical ingredient is lemborexant, which is an orexin receptor antagonist that inhibits orexin signaling through competitive binding to orexin receptors (OX1R and OX2R). Orexin is a chemical substance naturally produced by the hypothalamus and is involved in sleep and wakefulness.

당사는 귀하의 웹사이트 이용을 더 잘 이해하기 위해 쿠키를 사용하고자 하며, 이는 향후 웹사이트 방문 시 귀하의 경험을 개선하는 데 도움이 될 것입니다. 브라우저 설정에서 이 설정을 변경할 수 있습니다. 쿠키 사용에 대한 자세한 내용은 개인정보 보호정책을 참조하세요.